Literature DB >> 16178518

Development of rabies DNA vaccine using a recombinant plasmid.

N Rai1, P Kaushik, A Rai.   

Abstract

A recombinant plasmid pTargeT.rabgp containing the glycoprotein (G) gene of Rabies virus (RV) was constructed and produced for immunogenicity studies on mice and dogs. The mice immunized twice with 50 microg or 100 microg of pTargeT.rabgp intramuscularly (i.m.), showed a serum antibody titer of 256 or 64, respectively 14 days post immunization (p.i.). When the vaccinated mice were challenged at 14 days p.i. with RV i.c., they were protected in 81.25% or 87.5%, respectively. A positive cell mediated immune response was observed by lymphocyte proliferation assay and macrophage migration inhibition test. These results indicate that the pTargeT.rabgp plasmid can be used as a rabies DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16178518

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  4 in total

Review 1.  DNA vaccines and their applications in veterinary practice: current perspectives.

Authors:  K Dhama; Mahesh Mahendran; P K Gupta; A Rai
Journal:  Vet Res Commun       Date:  2008-04-19       Impact factor: 2.459

Review 2.  The Key Role of Nucleic Acid Vaccines for One Health.

Authors:  Anders Fomsgaard; Margaret A Liu
Journal:  Viruses       Date:  2021-02-08       Impact factor: 5.048

3.  Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review.

Authors:  Jae Kyung Lee; Ok Sarah Shin
Journal:  J Yeungnam Med Sci       Date:  2022-02-14

4.  Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge.

Authors:  Manpreet Kaur; Anant Rai; Rakesh Bhatnagar
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.